Please assess the completion status of the following clinical trial:

Trial Title: A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Documented human immunodeficiency virus type 1 (HIV-1) infection~* Never been treated with an antiretroviral (ARV) treatment or therapeutic HIV vaccine, or received less than or equal to 2 weeks treatment prior to screening with an nucleoside reverse transcriptase inhibitors~* HIV-1 plasma viral load above 5000 HIV-1 RNA copies per milliliter, at screening~* Cortisol of at least 550 nano moles per liter (19.9 microgram per deciliter) at screening~* Sensitivity to investigator selected nucleosides, at screening~Exclusion Criteria:~* Currently having active Acquired Immunodeficiency Syndrome (AIDS) defining illness~* Known or suspected acute (primary) HIV-1 infection~* Any current or history of adrenal disorder, and an acute hepatitis A, B, or C infection~* Documented genotypic evidence of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) resistance at screening~* Pregnant or breastfeeding females~* Not agree to protocol-defined effective use of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMC278 25 mg (Type: EXPERIMENTAL): Participants will receive TMC278 25 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
- TMC278 75 mg (Type: EXPERIMENTAL): Participants will receive TMC278 75 mg once daily up to Week 144. Later on, participants will receive TMC278 25 mg once daily up to Week 240.
- TMC278 150 mg (Type: EXPERIMENTAL): Participants will receive TMC278 150 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
- Efavirenz (Type: ACTIVE_COMPARATOR): Participants will receive efavirenz 600 mg once daily up to Week 96. Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.

Based on this trial design, predict the completion outcome and termination type (if applicable).